VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

References

• Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2). J ThoracOncol 2012; 7:1490-502; PMID:22982650; http://dx.doi.org/10.1097/JTO.0b013e318265b2b5
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57; PMID:19692680; http://dx.doi.org/10.1056/NEJMoa0810699
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-94; PMID:23724913; http://dx.doi.org/10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Binder D, Hegenbarth K. Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol 2013; 7:221-34; PMID:24179413; http://dx.doi.org/10.4137/CMO.S10269
   PubMedGoogle Scholar
• Konishi T, Huang CL, Adachi M, Taki T, Inufusa H, Kodama K, Kohno N, Miyake M. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers. Int J Oncol 2000; 16:501-11; PMID:10675482
   PubMed Web of Science ®Google Scholar
• Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006; 66:4198-207; PMID:16618742; http://dx.doi.org/10.1158/0008-5472.CAN-05-3842
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9; PMID:9377574
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603-669
   PubMed Web of Science ®Google Scholar
• Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull 2011; 34:1785-8; PMID:22130231; http://dx.doi.org/10.1248/bpb.34.1785
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J BiolChem 2006; 281:23514-24; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy ClinImmunol 2001; 108:250-7; PMID:11496242; http://dx.doi.org/10.1067/mai.2001.116576
   PubMed Web of Science ®Google Scholar
• Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. PharmRes 2008; 25:1318-26; PMID:18030605; http://dx.doi.org/10.1007/s11095-007-9481-3
   PubMed Web of Science ®Google Scholar
• Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, et al. The airways, a novel route for delivering monoclonal antibodies to treat lung tumors. Pharm Res 2011; 28:2147-56; PMID:21491145; http://dx.doi.org/10.1007/s11095-011-0442-5
   PubMed Web of Science ®Google Scholar
• Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111-6; PMID:11323676; http://dx.doi.org/10.1038/35074129
   PubMed Web of Science ®Google Scholar
• Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. ProcNatlAcadSci U S A 2007; 104:3478-83; PMID:17360669; http://dx.doi.org/10.1073/pnas.0611492104
   PubMed Web of Science ®Google Scholar
• Korsisaari N, Ross J, Wu X, Kowanetz M, Pal N, Hall L, Eastham-Anderson J, Forrest WF, Van Bruggen N, Peale FV, et al. Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1. Clin Cancer Res 2008; 14:249-58; PMID:18172277; http://dx.doi.org/10.1158/1078-0432.CCR-07-1552
   PubMed Web of Science ®Google Scholar
• Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J BiolChem 2006; 281:951-61; PMID:16278208; http://dx.doi.org/10.1074/jbc.M508199200
   PubMed Web of Science ®Google Scholar
• Yu L, Wu X, Cheng Z, Lee CV, Le Couter J, Campa C, Fuh G, Lowman H, Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49:522-7; PMID:18234994; http://dx.doi.org/10.1167/iovs.07-1175
   PubMed Web of Science ®Google Scholar
• Glaw JT, Skalak TC, Peirce SM. Inhibition of canonical Wnt signaling increases microvascular hemorrhaging and venular remodeling in adult rats. Microcirculation 2010; 17:348-57; PMID:20618692
   PubMed Web of Science ®Google Scholar
• Ko HC, Milthorpe BK, Mc Farland CD. Engineering thick tissues–the vascularisation problem. Eur Cell Mater 2007; 14:1-18, discussion 18-9; PMID:17654452
   PubMed Web of Science ®Google Scholar
• Ban HS, Uno M, Nakamura H. Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. Cancer Lett 2010; 296:17-26; PMID:20378243; http://dx.doi.org/10.1016/j.canlet.2010.03.010
   PubMed Web of Science ®Google Scholar
• De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev ClinOncol 2011; 8:393-404; PMID:21629216; http://dx.doi.org/10.1038/nrclinonc.2011.83
   PubMed Web of Science ®Google Scholar
• Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006; 66:3639-48; PMID:16585189; http://dx.doi.org/10.1158/0008-5472.CAN-05-3295
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Shoemaker RH, Melillo G. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle 2009; 8:4040-3; PMID:19923892; http://dx.doi.org/10.4161/cc.8.24.10145
   PubMed Web of Science ®Google Scholar
• Wu JM, Staton CA. Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin Drug Discov 2012; 7:723-43; PMID:22716277; http://dx.doi.org/10.1517/17460441.2012.695774
   PubMed Web of Science ®Google Scholar
• Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 2012; 114:237-67; PMID:22588059; http://dx.doi.org/10.1016/B978-0-12-386503-8.00006-5
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Yan H, Lu D, Ye Z, Hao J, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012; 120:2330-9; PMID:22718841; http://dx.doi.org/10.1182/blood-2012-01-406108
   PubMed Web of Science ®Google Scholar
• Belmont L, Rabbe N, Antoine M, Cathelin D, Guignabert C, Kurie J, Cadranel J, Wislez M. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer 2014; 134:765-77; PMID:23913633; http://dx.doi.org/10.1002/ijc.28413
   PubMed Web of Science ®Google Scholar
• Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert OpinTher Targets 2010; 14:1047-57; PMID:20854179; http://dx.doi.org/10.1517/14728222.2010.511617
   PubMed Web of Science ®Google Scholar
• Epstein RJ. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic. Cancer Metastasis Rev 2007; 26:443-52; PMID:17786538; http://dx.doi.org/10.1007/s10555-007-9071-1
   PubMed Web of Science ®Google Scholar
• Bonnesen B, Pappot H, Holmstav J, Skov BG. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis. Lung Cancer 2009; 66:314-8; PMID:19324448; http://dx.doi.org/10.1016/j.lungcan.2009.02.013
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49; PMID:18463380; http://dx.doi.org/10.1056/NEJMra0706596
   PubMed Web of Science ®Google Scholar
• Casulli S, Topçu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, Bayry J, Kaveri SV, Elbim C. A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One 2011; 6:e26469; PMID:22065996; http://dx.doi.org/10.1371/journal.pone.0026469
   PubMedGoogle Scholar
• von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J, Winkler F. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 2011; 17:6192-205; PMID:21788357; http://dx.doi.org/10.1158/1078-0432.CCR-10-1868
   PubMed Web of Science ®Google Scholar
• Pushkarev VM, Starenki DV, Saenko VA, Pushkarev VV, Kovzun OI, Tronko MD, Popadiuk ID, Yamashita S. Differential effects of low and high doses of Taxol in anaplastic thyroid cancer cells: possible implication of the Pin1 prolyl isomerase. ExpOncol 2008; 30:190-4; PMID:18806740
   PubMedGoogle Scholar
• Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104:228-39; PMID:22247021; http://dx.doi.org/10.1093/jnci/djr523
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. ProcNatlAcadSci U S A 2007; 104:17069-74; PMID:17942672; http://dx.doi.org/10.1073/pnas.0708148104
   PubMed Web of Science ®Google Scholar
• Moserle L, Casanovas O. Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer. EMBO Mol Med 2012; 4:168-70; PMID:22323445; http://dx.doi.org/10.1002/emmm.201200206
   PubMed Web of Science ®Google Scholar
• Liu W, Xu J, Wang M, Wang Q, Bi Y, Han M. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011; 39:1213-20; PMID:21785819
   PubMed Web of Science ®Google Scholar
• Bitonti AJ, Dumont JA. Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev 2006; 58:1106-18; PMID:16997417; http://dx.doi.org/10.1016/j.addr.2006.07.015
   PubMed Web of Science ®Google Scholar
• Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005; 18:294-303; PMID:16181004; http://dx.doi.org/10.1089/jam.2005.18.294
   PubMedGoogle Scholar
• Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. ClinPharmacokinet 2013; 52:83-124; PMID:23299465; http://dx.doi.org/10.1007/s40262-012-0027-4
   PubMed Web of Science ®Google Scholar
• RCoreTeam. Computational Many-Particle Physics. In: Fehske H, Schneider R, Weiße A, eds.: Springer Berlin Heidelberg, 2008.
   Google Scholar
• Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9:E60-83; PMID:17408237; http://dx.doi.org/10.1208/aapsj0901007
   PubMedGoogle Scholar